Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 3 completed trials

    Completion Rate
    50%(3/6)
    Active Trials
    0(0%)
    Results Posted
    67%(2 trials)
    Terminated
    3(50%)

    Phase Distribution

    Phase 1
    5
    83%
    Phase 2
    1
    17%

    Phase Distribution

    5

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution6 total trials
    Phase 1Safety & dosage
    5(83.3%)
    Phase 2Efficacy & side effects
    1(16.7%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    50.0%

    3 of 6 finished

    Non-Completion Rate

    50.0%

    3 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    6

    all time

    Status Distribution
    Completed(3)
    Terminated(3)

    Detailed Status

    Completed3
    Terminated3

    Development Timeline

    Analytics

    Development Status

    Total Trials
    6
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 15 (83.3%)
    Phase 21 (16.7%)

    Trials by Status

    completed350%
    terminated350%

    Recent Activity

    0 active trials
    Showing 5 of 6
    terminatedphase_1

    Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

    NCT00460460
    completedphase_2

    A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

    NCT00661609
    terminatedphase_1

    Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

    NCT00486265
    terminatedphase_1

    Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

    NCT00471367
    completedphase_1

    A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

    NCT00613652
    View all 6 trials

    Clinical Trials (6)

    Showing 6 of 6 trials
    NCT00460460Phase 1

    Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

    Terminated
    NCT00661609Phase 2

    A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

    Completed
    NCT00486265Phase 1

    Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

    Terminated
    NCT00471367Phase 1

    Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

    Terminated
    NCT00613652Phase 1

    A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

    Completed
    NCT00389389Phase 1

    Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

    Completed

    All 6 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    6